Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | KMT2A rearrange FLT3 exon 14 ins |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KMT2A rearrange FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Revumenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Revuforj (revumenib) reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement (MLL-r) and FLT3-ITD compared to vehicle-treated, but only inhibited cell viability after prolonged treatment in culture (PMID: 35017466). | 35017466 | |
KMT2A rearrange FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Revumenib + Venetoclax | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Revuforj (revumenib) and Venclexta (venetoclax) reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement and FLT3-ITD compared to either treatment alone, and demonstrated synergy in culture, resulting in decreased viability (PMID: 35017466). | 35017466 |